JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
139.65
+0.45 (+0.32%)
At close: 4:01PM EDT

139.50 -0.15 (-0.11%)
Pre-Market: 8:35AM EDT

Stock chart is not supported by your current browser
Previous Close139.20
Open138.52
Bid139.25 x 1400
Ask139.79 x 900
Day's Range137.96 - 139.77
52 Week Range118.62 - 148.99
Volume4,934,330
Avg. Volume6,520,388
Market Cap371.856B
Beta (3Y Monthly)0.69
PE Ratio (TTM)25.88
EPS (TTM)5.40
Earnings DateJul 16, 2019
Forward Dividend & Yield3.60 (2.58%)
Ex-Dividend Date2019-02-25
1y Target Est147.53
Trade prices are not sourced from all markets
  • Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1
    Zacks1 hour ago

    Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1

    Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.

  • 5 Top Stock Trades for Friday Morning: Facebook, 3M, Tesla and Comcast
    InvestorPlace16 hours ago

    5 Top Stock Trades for Friday Morning: Facebook, 3M, Tesla and Comcast

    It was another sleepy day for the major indices, but not a quiet day with individual stocks. We saw some massive moves in the market following earnings, so let's get started and see some top stock trades for Friday. Keep an eye on Realty Income (NYSE:O) as it bounces off trend support into potential moving average resistance, as well as Johnson & Johnson (NYSE:JNJ). JNJ put in another higher low on the chart, increasing the odds of a breakout over $140. Finally, Ford (NYSE:F) and Intel (NASDAQ:INTC) report earnings tonight, two trades we laid out on Wednesday. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Top Stock Trades for Tomorrow 1: FacebookShares of Facebook (NASDAQ:FB) are popping on Thursday, up 6.4% after the company impressed with its earnings results. After consolidating over $180 for the past few weeks, FB stock is on the move once again. It pushed through that important $185 to $190 zone, the former of which also sports the 61.8% Fibonacci retracement for the 52-week range. Shares backed off $200, as profit takers unloaded a bit after the big rally this year. * 7 Dividend Stocks That Could Double Over the Next Five Years Now what? I want to see FB stock hold this $185 to $190 area as support now. Ideally, FB would give us a pullback into this area, allowing its moving averages to catch up a bit and consolidate some of this move. If it holds, it increases the odds of a move back over $200. That said, the bullish momentum could continue with a pullback too. Top Stock Trades for Tomorrow 2: 3M CoNot making such a healthy move on Thursday is 3M Co (NYSE:MMM). Disappointing earnings results drilled the stock to the tune of 13%. Will support buoy the stock and keep it from more losses? $190-ish has played a role in the past and $192 also has the 61.8% Fibonacci retracement for the 52-week range, so it's certainly possible. That said, $180 had to make a stand twice in the fourth quarter. With the 200-week at $182 and with a quarter like this, I wouldn't be surprised to see some more selling before buyers make a big stand. See how it handles $190 to $192-ish on Friday. Top Stock Trades for Tomorrow 3: AltriaAltria (NYSE:MO) is also getting drilled on earnings, down 6% on the day. The stock has been making a series of lower highs and the 200-week moving average acted as resistance over the past few weeks. That doesn't bode well for intermediate term bulls out there. MO is now below all three major moving averages on the weekly chart, with no real support coming into play until $48. It's possible it finds a bottom and reverses before that point, but shares look unattractive until $52. Unless it reclaims $52, MO is in no man's land. If it does recover, see how it handles the 20-week and 50-week moving averages near $54. Top Stock Trades for Tomorrow 4: ComcastComcast (NASDAQ:CMCSA) was a winner on Thursday, rallying 3% on its quarterly earnings results. It cleared $40 a few weeks ago and this week's gains only add to bulls' recent optimism. A potential deal with Disney (NYSE:DIS) over Comcast's stake in Hulu could be a win-win for both companies too. This week's low came right at the stock's prior weekly closing high in January 2018. A grind up past $44 -- near the stock's highs -- is definitely possible. CMCSA would look interesting on a pullback though, especially down into this week's lows near $42. It's where the 10-week moving average and uptrend support come into play too. Top Stock Trades for Tomorrow 5: TeslaTesla (NASDAQ:TSLA) stock did not decline the way many bears were hoping on Thursday. That's despite the automaker missing on earnings and revenue expectations. In any regard, the stock is showing signs of a breakdown.Shares have been building a base under the 200-week moving average and remain in a steep downtrend. Below the $242 area and TSLA will be making multi-year lows. * 5 Hot Dividend Stocks to Buy as the Weather Heats Up From the long side, this one does not look tempting. For that to change, it needs to hold this area and get back above its 200-week moving average. On top of that, it needs to clear downtrend resistance. If it doesn't, a flush lower is more than possible.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long JNJ. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks That Could Double Over the Next Five Years * 6 S&P 500 Stocks Ready to Break Out * 5 Mining ETFs to Dig Into Compare Brokers The post 5 Top Stock Trades for Friday Morning: Facebook, 3M, Tesla and Comcast appeared first on InvestorPlace.

  • The Top 10 Biotechnology Companies (JNJ, ROG.VX)
    Investopedia18 hours ago

    The Top 10 Biotechnology Companies (JNJ, ROG.VX)

    Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

  • Here's Why The Bacteria In Your Gut Could Be A Blockbuster Opportunity
    Investor's Business Daily20 hours ago

    Here's Why The Bacteria In Your Gut Could Be A Blockbuster Opportunity

    Big Pharma is rapidly increasing its investments into biotech companies aiming to treat disease by targeting the microbiome. Some are also working on using bacterial strains as drugs.

  • Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?
    Zacks21 hours ago

    Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?

    Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive first-quarter sales. However, genericization of key drugs and increasing competition are concerns.

  • AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View
    Zacks21 hours ago

    AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View

    AbbVie (ABBV) beats first-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.

  • MarketWatch22 hours ago

    Johnson & Johnson raises quarterly dividend by 5.6% to 95 cents a share

    Consumer giant Johnson & Johnson said Thursday its board has approved a 5.6% increase in its quarterly dividend to 95 cents a share. The new dividend will be payable June 11 to shareholders of record as of May 28. Shares were slightly lower, but have gained 9.7% in the last 12 months, while the Dow Jones Industrial Average , which counts it as a member, has gained 9.4%.

  • Johnson & Johnson Announces Dividend Increase of 5.6%
    PR Newswire22 hours ago

    Johnson & Johnson Announces Dividend Increase of 5.6%

    NEW BRUNSWICK, N.J., April 25, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a 5.6% increase in the quarterly dividend rate, from $0.90 per share to $0.95 per share.  The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, N.J. "In recognition of our 2018 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the quarterly dividend for the 57th consecutive year," said Alex Gorsky, Chairman and Chief Executive Officer of the company. At the new rate, the indicated dividend on an annual basis is $3.80 per share compared to the previous rate of $3.60 per share.  The next quarterly dividend is payable on June 11, 2019 to shareholders of record as of the close of business on May 28, 2019.

  • Reutersyesterday

    India alleges big multinationals did not pass on tax benefits: source

    Indian tax authorities have alleged that a number of big multinational companies have not passed on benefits from a tax cut to customers, a senior government official told Reuters. The official said, for example, that the tax authorities have alleged that U.S. consumer goods maker Procter & Gamble did not pass on more than $35 million in tax benefits which were meant to have gone to its customers. Separately, the authorities are also investigating South Korea's Samsung Electronics and U.S. drug maker Johnson & Johnson among others, the senior government official, speaking on condition of anonymity, said.

  • Reutersyesterday

    India alleges big multinationals did not pass on tax benefits -source

    Indian tax authorities have alleged that a number of big multinational companies have not passed on benefits from a tax cut to customers, a senior government official told Reuters. The official said, for example, that the tax authorities have alleged that U.S. consumer goods maker Procter & Gamble did not pass on more than $35 million in tax benefits which were meant to have gone to its customers. Separately, the authorities are also investigating South Korea's Samsung Electronics and U.S. drug maker Johnson & Johnson among others, the senior government official, speaking on condition of anonymity, said.

  • Johnson & Johnson to Host Pharmaceutical Business Review
    PR Newswire2 days ago

    Johnson & Johnson to Host Pharmaceutical Business Review

    NEW BRUNSWICK, N.J. , April 24, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceutical businesses for the investment community beginning at 8:30 a.m. (Eastern Time) ...

  • Everything You Need to Know About Investing in Healthcare
    Motley Fool2 days ago

    Everything You Need to Know About Investing in Healthcare

    The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.

  • 7 Companies With Unacceptable CEO-Worker Wage Gaps
    InvestorPlace2 days ago

    7 Companies With Unacceptable CEO-Worker Wage Gaps

    Nothing frustrates investors more than companies failing to deliver for shareholders but managing to pay the CEO of those companies a King's ransom.On April 18, I covered 7 Companies That Are Closing the CEO-Worker Wage Gap in America. These are the kind of companies I like to write about. The ones that aren't sacrificing the financial happiness of the rank-and-file employees to keep the chief executives in a lavish lifestyle. The reality is that companies who pay their CEO significantly more than the salaries of the workers tend to experience poor shareholder returns. A recent study reported by Bloomberg and quoted in my previous article showed that the 100 S&P 500 companies with the lowest CEO pay outperformed the 100 with the highest by more than double between 2008 and 2018. InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo, whether you want to focus on the seven companies who've paid their CEOs outrageous sums in relation to the average employee or just the seven that have spent too much, the names in this article have unacceptable CEO-Worker wage gaps. * 10 Stocks to Sell Before They Give Back 2019 Gains Ultimately, this skewing of compensation will result in their stock's demise. American International Group (AIG)Source: Eflon via Flickr (Modified)Pay Ratio: 697:1Earning almost 700 times American International Group's (NYSE:AIG) median pay of $64,186, CEO Brian Duperreault is doing alright for himself. The company will argue that the CEO's 2017 pay was only that high because it had to pay $12 million to Duperreault to make up for the unvested equity awards he left behind when joining the insurance company in May 2017. Assuming the median pay at AIG didn't move much in 2018, Duperreault made a more pedestrian $16 million this past year or 249 times the average employee. How's AIG stock done since Duperreault was hired in 2017?AIG stock is down 21.5% in the 23 months since. If AIG doesn't get going soon, 249 times the median pay is going to appear more outrageous than it already is. CBS (CBS)Source: Shutterstock Pay Ratio: 595:1Once upon a time, former CBS (NYSE:CBS) CEO Les Moonves was considered a bit of a CEO celebrity, having turned the network into a TV powerhouse. And then the sexual harassment claims came out that painted the picture of a lecherous man using his power to hit on women. CBS investigators interviewed as many as 300 people about Moonves last December as part of its investigation into Moonves' actions and whether they breached the CEO's employment contract. The company found that they did, terminating him with cause and withholding Moonves' $120 million severance package. However, don't feel bad for the man. Between 2016-2018, Moonves made $186 million in total compensation over those three years, an average of $62 million -- 531 times the company's very high median pay of $116,654. CBS employees aren't exactly starving and yet they still made considerably less than Moonves over those three years. In that same period, CBS stock went sideways, delivering annual total returns of 36%, -6%, and -25% in 2016, 2017, and 2018 respectively. * 15 Stocks Sitting on Huge Piles of Cash If you were a CBS shareholder over the past three years, you got royally hosed, as did the employees. Discovery Communications (DISCA)Source: www.glynlowe.com via FlickrPay Ratio: 522:1I remember when Discovery Communications (NASDAQ:DISCA) launched the Oprah Winfrey Network (OWN) in January 2011. The 50/50 joint venture between the television broadcaster and one of America's wealthiest women was thought to be a slam dunk despite the more than $500 million DISCA invested in the cable network in the first two years of its existence. CEO David Zaslav, who's been the CEO for more than 12 years, was thought to be a brilliant judge of talent. However, OWN never really hit the big time when it comes to cable networks, and in December 2017, Winfrey sold half of her stake for $70 million, leaving Discovery with 75% control. However, that puts the value of OWN at approximately $280 million, much less than the amount invested by Discovery to get it up and running. And for that, Discovery shareholders paid Zaslav $208.9 million between 2016-2018, including a staggering $129.4 million in 2018, much of it ($102 million) in stock awards this past year. Also, Zaslav had $21 million of Discovery stock vest in 2018 in addition to the $129.4 million in total compensation. Over the past three years through April 18, DISCA shareholders have received an annualized total return of 1.8%, well behind the S&P 500 and other peers in the media business. TripAdvisor (TRIP)Source: JD Lasica/Cruiseable.com via FlickrPay Ratio: 481:1Any day now, TripAdvisor (NASDAQ:TRIP) is going to release its 2018 proxy showing CEO Stephen Kaufer's total compensation for the past year. In 2017, Kaufer was paid a total of $47.9 million in total with 98% in stock and option awards. If you exclude the stock and option awards, Kaufer only made a little over $1 million in 2017, around the same amount as the two previous years. So, if you're wondering why TRIP made the list, consider that Kaufer co-founded the company in February 2000. He would have a made a significant amount of money when TripAdvisor was sold to Expedia (NASDAQ:EXPE) in 2004 and then some more when it was spun-off in December 2011. Over the past three years, TRIP stock's delivered an annualized total return of -7.5% through April 18. And for that, Kaufer got almost $50 million in stock options and awards in 2017. * 10 High-Yielding Dividend Stocks That Won't Wilt It hardly seems worth it. That's especially true if you're one of the hardworking TripAdvisor employees earning just under $100,000 a year. Johnson & Johnson (JNJ)Source: Shutterstock Pay Ratio: 452:1It seems odd that I would pick on Johnson & Johnson (NYSE:JNJ), a stock that's delivered an annualized total return of 10% over the past three years through April 18, but that's what I'm going to do. In the past three years, CEO Alex Gorsky brought home cumulative total compensation of $76.8 million; not exactly Les Moonves territory, but much more substantial than the company's median pay of $66,000.In February of this year, I wondered if Gorsky was earning his pay. I argued that because JNJ shareholders had done well since he became CEO in December 2012, they probably wouldn't care. However, like America itself, if you don't speak up about what's wrong, you'll have to settle for whatever you get. Oh, and don't forget that Gorsky also made $43 million in 2018 through the CEOs stock options and awards that vested during the year. That's on top of his $20.1 million in total compensation. If you add that in, the pay ratio jumps to almost 1,000:1. Do you still think Gorsky's worth it? AT&T (T)Source: Shutterstock Pay Ratio: 366:1I've never been a fan of the AT&T (NYSE:T) purchase of Warner Media. To me, it was adding too much debt to a company that already had a significant amount. Some would call this type of acquisition by CEO Randall Stephenson a vanity project. I wouldn't disagree. Since AT&T closed the Warner Media merger in June 2018, T stock's appreciated by 5.8% including dividends. Considering its dividend is currently yielding 5.9%, most if not all its gains are from dividends. In the last three years (2016-2018), Randall Stephenson earned $86.2 million in total compensation and another $40.6 million in stock awards for an annual average of $42.3 million for a media ratio of 539:1, 47% higher than the ratio listed above. * 7 Red-Hot E-Commerce Stocks to Consider Until Stephenson gets the debt down, you can assume that the CEO will continue to deliver underwhelming returns for shareholders. Regeneron Pharmaceuticals (REGN)Source: Shutterstock Pay Ratio: 215:1The Regeneron Pharmaceuticals (NASDAQ:REGN) pay ratio is the least offensive of the seven companies on this list. I picked Regeneron primarily because it had one of the S&P 500's highest median annual pay at $123,418. It's one thing to have a pay ratio over 200 when your employees make $40,000 a year, but when they make three times that, to crank up the CEO-Worker wage gap by more than 200 times median pay is quite the accomplishment. So, how did CEO and founder Dr. Leonard Schleifer do it? Salary, a little bit of non-equity compensation, a $2.9 million cash bonus, and a whole lot of option awards. Over the past three years, Schleifer's been awarded $89.9 million in options. Also, in 2017 alone, Schleifer realized $90.8 million on the exercise of 250,000 shares. That right there doubles his compensation over the past three years, and I haven't even taken into account 2016 or 2015. If you add those in, the Regeneron pay ratio also balloons into the stratosphere.With almost six million shares of Regeneron stock, you would think the board and founder could come to some agreement as Warren Buffett has at his company that doesn't reek of greed. You know what they say, "If you own a successful business and want to relate to your staff, don't drive to work every day in a Bentley."I guess option awards is the good doctor's version of a Bentley. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Oversold Stocks to Run From * 7 Red-Hot E-Commerce Stocks to Consider * 4 Stocks Surging on Earnings Surprises Compare Brokers The post 7 Companies With Unacceptable CEO-Worker Wage Gaps appeared first on InvestorPlace.

  • Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales
    Zacks2 days ago

    Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales

    Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

  • Approach Microsoft Stock Cautiously as it Goes Into Earnings
    InvestorPlace2 days ago

    Approach Microsoft Stock Cautiously as it Goes Into Earnings

    Microsoft (NASDAQ:MSFT) stock reports earnings Wednesday after the market close. The company usually beats estimates, so the actual numbers may have little effect on Microsoft stock. However, both the stock price and the valuation continue to approach elevated levels.Source: Shutterstock Moreover, other factors could cause a near-term pullback. Although MSFT stock looks solid for the long term, investors should probably not buy this equity going into earnings. Expect Higher Earnings and RevenuesFor its fiscal third quarter, analysts forecast consensus earnings of $1 per share. The company earned 95 cents per share in the same quarter last year. They also expect revenues of $29.84 billion. If this prediction proves correct, it will represent an 11.3% increase from year-ago levels, when the Redmond, Washington-based software giant brought in $26.82 billion.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvestors should also note that Microsoft beat earnings in each of the last four quarters. MSFT may have only beaten estimates by one penny per share in the previous report. Still, most traders will probably expect that streak to continue in the upcoming release. Microsoft Stock Remains Solid for the Long TermIn many respects, things have never looked better for Microsoft stock. MSFT trades near all-time highs. The tech giant once depended on its operating system. Today it has turned itself around and boosted its profits by becoming one of the premier cloud computing companies. Cloud profits explain why Wall Street forecasts average profit increases of 14.5% per year for the next five years. * 10 Stocks to Sell Before They Give Back 2019 Gains Today, only Amazon (NASDAQ:AMZN) surpasses Microsoft in cloud-based revenues. It has also become a contender with Amazon for JEDI, a $10 billion project that would accelerate the Pentagon's adoption of cloud platforms.The company also continues to maintain one of the most solid balance sheets in corporate America. Its cash hoard of $127.66 billion may lag that of Apple (NASDAQ:AAPL), but it remains the only company other than Johnson & Johnson (NYSE:JNJ) to hold a AAA credit rating. That alone means that long-term investors should probably stay in MSFT and collect the $1.84 per share in annual dividends. Consider Exercising Caution at These LevelsStill, as it approaches the $1 trillion market cap for the first time, many wonder whether prospective buyers should get in now. The price-to-earnings (P/E) ratio has remained elevated since soon after Satya Nadella took over as CEO in 2014. Its current 29 trailing P/E ratio compares well to the average multiple of 33.3 over the last five years.However, other ratios point to overvaluation in Microsoft stock. The stock has risen more than 30% from its December lows. Moreover, MSFT trades at more than eight times sales, and its price-to-book ratio now exceeds 10. MSFT faces other possible issues. As my colleague Will Ashworth points out, allegations of sexual harassment within the company could lead to traders questioning the equity's multiple. Moreover, the odds slightly favor Amazon on the JEDI contract.To be sure, any significant drop in Microsoft stock would likely create a buying opportunity. However, new buyers should probably wait for that time before opening a position. Final Thoughts on MSFT StockAlthough Microsoft stock remains a solid, long-term pick, near-term factors probably mean that new investors should wait to buy. Yes, analysts expect earnings and revenue to rise on a year-over-year basis. Also, if the recent history of MSFT stock serves as an indication, it will likely beat those earnings.However, the P/E ratio has become elevated. Moreover, issues related to "me too" remain a cause for concern. With the stock up more than 30% in the last four months alone, any bad news could lead to a short-term drop in the equity.None of this news will make Microsoft stock a sell except to very-short-term traders. However, after the recent move higher, new buyers should probably hold off on MSFT going into earnings.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Oversold Stocks to Run From * 7 Red-Hot E-Commerce Stocks to Consider * 4 Stocks Surging on Earnings Surprises Compare Brokers The post Approach Microsoft Stock Cautiously as it Goes Into Earnings appeared first on InvestorPlace.

  • Benzinga2 days ago

    Jim Cramer Gives His Opinion On Barrick Gold, Canopy Growth, EA, Johnson & Johnson And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he likes CarMax, Inc (NYSE: KMX ) in the auto dealerships space, but he will take a closer look at CarGurus Inc (NASDAQ: CARG ). Instead ...

  • Exploring JNJ’s Key Oncology Assets in the First Quarter
    Market Realist2 days ago

    Exploring JNJ’s Key Oncology Assets in the First Quarter

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Imbruvica’s trendsIn the first quarter, Johnson & Johnson (JNJ) and AbbVie’s (ABBV) Imbruvica reported 40% YoY (year-over-year) growth in

  • CNBC3 days ago

    Cramer's lightning round: I'm sticking with this gold stock pick

    It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.CarGurus Inc. CARG : "Well, I gotta tell you my viewers, including you Scott, are smarter than I am.

  • Pharmaceutical Segment: A Key Revenue Driver for JNJ in Q1
    Market Realist3 days ago

    Pharmaceutical Segment: A Key Revenue Driver for JNJ in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performanceIn the first quarter, Johnson & Johnson’s (JNJ) Pharmaceutical segment reported 7.9% YoY (year-over-year) growth in worldwide

  • Motley Fool3 days ago

    Prescription for Success?

    Prescription drug sales, the future of Hulu, and more.

  • JNJ’s Consumer Business: International Market Trends in Q1
    Market Realist3 days ago

    JNJ’s Consumer Business: International Market Trends in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC business performance in international markets In the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported a 3% YoY

  • JNJ’s OTC, Oral Care, and Wound Care Businesses: Key Trends in Q1
    Market Realist3 days ago

    JNJ’s OTC, Oral Care, and Wound Care Businesses: Key Trends in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC businessIn the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported revenue of $1.09 billion, reflecting YoY

  • Beauty: A Key Growth Driver of JNJ’s Consumer Segment in Q1
    Market Realist4 days ago

    Beauty: A Key Growth Driver of JNJ’s Consumer Segment in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performance In the first quarter, Johnson & Johnson’s (JNJ) Consumer segment reported 2.2% YoY (year-over-year) growth in worldwide

  • Mr. Wonderful, Oz Pearlman and the Beardstown Ladies make their first round stock picks
    CNBC Videos17 hours ago

    Mr. Wonderful, Oz Pearlman and the Beardstown Ladies make their first round stock picks

    CNBC's "Power Lunch" hosts the 2019 Stock Draft. O'Shares ETFs chairman Kevin O'Leary, Wall Street mentalist Oz Pearlman, and the Beardstown Ladies make their first round picks. This year's other participants include celebrity chef Bobby Flay, professional poker player Maria Ho, New York Mets pitcher Noah Syndergaard, former NFL defensive end Jarvis Green, entrepreneur and author Bethenny Frankel and former NFL player Nick Lowery, and Seymour Asset Management founder Tim Seymour.

  • Cramer's lightning round: I'm sticking with this gold stock pick
    CNBC Videos3 days ago

    Cramer's lightning round: I'm sticking with this gold stock pick

    Jim Cramer takes calls and gives his thoughts about different stocks in lightning speed.